Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy

BACKGROUND: Immune checkpoint inhibitors (ICIs) are now a first-line treatment option for patients with pleural mesothelioma with the recent approval of ipilimumab and nivolumab. Mesothelioma has a low tumor mutation burden and no robust predictors of survival with ICI. Since ICIs enable adaptive an...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Aakash P, Kosari, Farhad, Disselhorst, Maria, Yin, Jun, Agahi, Alireza, Peikert, Tobias, Udell, Julia, Johnson, Sarah H, Smadbeck, James, Murphy, Stephen, Karagouga, Giannoula, McCune, Alexa, Schaefer-Klein, Janet, Borad, Mitesh J, Cheville, John, Vasmatzis, George, Baas, Paul, Mansfield, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255162/
https://www.ncbi.nlm.nih.gov/pubmed/37279993
http://dx.doi.org/10.1136/jitc-2022-006035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255162/
https://www.ncbi.nlm.nih.gov/pubmed/37279993
http://dx.doi.org/10.1136/jitc-2022-006035

Ejemplares similares